Accord Gets EMA Support For Arsenic Trioxide
Positive opinions on Accord’s arsenic trioxide, Kabi’s bortezomib and Orphelia Pharma’s clofarabine were among the latest rafts of recommendations for approval made by the European Medicines Agency’s CHMP.
You may also be interested in...
Stada says it is not only first-to-market with generic bortezomib in major European markets. It is also offering a more convenient ready-to-use solution.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.